Pomalidomide 4mgCapsule
Anti-Cancer

Pomalidomide 4mg

Pomalidomide

Third-generation immunomodulatory imide drug with enhanced anti-myeloma activity compared to thalidomide and lenalidomide, approved for relapsed/refractory multiple myeloma after at least two prior therapies including lenalidomide and bortezomib. Natco and Hetero supply affordable 1mg, 2mg, and 4mg capsules for global haematological oncology export.

Strengths

1mg / 2mg / 4mg

Packing

21 capsules/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Pomalidomide 1mg / 2mg / 4mg
Dosage Form
Capsule
Available Strengths
1mg / 2mg / 4mg
Packing
21 capsules/bottle
Route of Administration
Oral, on empty stomach
Dosage
4mg once daily on days 1-21 of 28-day cycles with dexamethasone
Indications
Relapsed/refractory multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor
Country of Origin
India (WHO-GMP Certified)
Storage
Store at 20-25°C
Shelf Life
24 months
Side Effects
Neutropenia, anemia, thrombocytopenia, fatigue, dizziness, constipation, nausea, back pain, DVT/PE
Precautions
Mandatory pregnancy prevention program (analog of thalidomide); VTE prophylaxis required; monitor CBC weekly for first 2 months; dose reduction for neutropenia; hepatotoxicity risk

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Need bulk pricing for Pomalidomide 4mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote